Vaxart (VXRT) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 11, 2020
Document Information [Line Items]
Entity Registrant Name	Vaxart, Inc.
Entity Central Index Key	0000072444
Trading Symbol	vxrt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		109,468,945
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common stock, $0.0001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 133,438	$ 13,526
Accounts receivable	250	3,619
Prepaid expenses and other current assets	1,903	453
Total current assets	135,591	17,598
Property and equipment, net	662	210
Right-of-use assets, net	2,591	1,990
Intangible assets, net	15,794	17,093
Other long-term assets	72	141
Total assets	154,710	37,032
Current liabilities:
Accounts payable	1,871	852
Current portion of operating lease liability	1,699	841
Liability related to sale of future royalties, current portion	3,008	2,916
Other accrued liabilities	3,724	4,565
Total current liabilities	10,302	9,174
Operating lease liability, net of current portion	1,032	1,472
Liability related to sale of future royalties, net of current portion	11,698	13,416
Other long-term liabilities		18
Total liabilities	23,032	24,080
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of September 30, 2020 and December 31, 2019
Common stock: $0.0001 par value; 150,000,000 shares authorized; 109,468,945 and 48,254,994 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	11	5
Additional paid-in capital	266,687	129,608
Accumulated deficit	(135,020)	(116,661)
Total stockholders’ equity	131,678	12,952
Total liabilities and stockholders’ equity	$ 154,710	$ 37,032

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	109,468,945	48,254,994
Common stock, shares outstanding (in shares)	109,468,945	48,254,994

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Revenue	$ 265	$ 454	$ 3,690	$ 5,946
Operating expenses:
Research and development	4,616	3,713	11,272	11,249
General and administrative	4,190	1,455	10,076	4,856
Restructuring costs	(952)		(849)
Total operating expenses	7,854	5,168	20,499	16,105
Operating loss	(7,589)	(4,714)	(16,809)	(10,159)
Other income and (expenses):
Interest income	5	58	69	97
Interest expense		(84)		(288)
Non-cash interest expense related to sale of future royalties	(464)	(500)	(1,401)	(1,560)
Foreign exchange gain (loss), net	(11)	11	(13)	(32)
Total other income and (expenses)	(470)	(515)	(1,345)	(1,783)
Net loss before income taxes	(8,059)	(5,229)	(18,154)	(11,942)
Provision for income taxes	26	31	205	294
Net loss	$ (8,085)	$ (5,260)	$ (18,359)	$ (12,236)
Net loss per share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.32)	$ (0.23)	$ (0.96)
Shares used to compute net loss per share - basic and diluted (in shares)	107,718,578	16,249,032	81,121,045	12,748,665
Customer Service Contracts [Member]
Revenue:
Revenue	$ 2	$ 94	$ 193	$ 94
Royalty [Member]
Revenue:
Revenue		8	2,962	3,736
Non Cash Royalty Revenue [Member]
Revenue:
Revenue	$ 263	$ 352	$ 535	$ 2,116

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	The September 2019 Offering [Member]Underwriters' Designees [Member]Common Stock [Member]	The September 2019 Offering [Member]Underwriters' Designees [Member]Additional Paid-in Capital [Member]	The September 2019 Offering [Member]Underwriters' Designees [Member]Retained Earnings [Member]	The September 2019 Offering [Member]Underwriters' Designees [Member]	The September 2019 Offering [Member]Common Stock [Member]	The September 2019 Offering [Member]Additional Paid-in Capital [Member]	The September 2019 Offering [Member]Retained Earnings [Member]	The September 2019 Offering [Member]	The April 2019 Offering [Member]Underwriters' Designees [Member]Common Stock [Member]	The April 2019 Offering [Member]Underwriters' Designees [Member]Additional Paid-in Capital [Member]	The April 2019 Offering [Member]Underwriters' Designees [Member]Retained Earnings [Member]	The April 2019 Offering [Member]Underwriters' Designees [Member]	The April 2019 Offering [Member]Common Stock [Member]	The April 2019 Offering [Member]Additional Paid-in Capital [Member]	The April 2019 Offering [Member]Retained Earnings [Member]	The April 2019 Offering [Member]	Placement Agents' Designees [Member]Common Stock [Member]	Placement Agents' Designees [Member]Additional Paid-in Capital [Member]	Placement Agents' Designees [Member]Retained Earnings [Member]	Placement Agents' Designees [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2018																									7,141,189				7,141,189
Balances at Dec. 31, 2018																							$ (27)	$ (27)	$ 1	$ 109,226	$ (98,016)	$ 11,211	$ 1	$ 109,226	$ (97,989)	$ 11,238
Issuance of common stock, net of offering costs (in shares)																													1,200,000
Issuance of common stock, net of offering costs																														2,440		2,440
Issuance of common stock upon exercise of common stock warrants																													1	1,082		$ 1,083
Issuance of common stock upon exercise of stock options (in shares)																																0
Stock-based compensation																														490		$ 490
Net loss																															(12,236)	(12,236)
Issuance of common stock and common stock warrants, net of offering costs (in shares)					26,124,828								925,455
Issuance of common stock and common stock warrants, net of offering costs					$ 3	$ 7,241		$ 7,244						$ 7,741		$ 7,741
Issuance of common stock warrants to placement agents’ designees		$ 497		$ 497						$ 333		$ 333						$ 100		$ 100
Issuance of common stock upon exercise of pre-funded warrants (in shares)																													10,832,122
Balances (in shares) at Sep. 30, 2019																													46,223,594
Balances at Sep. 30, 2019																													$ 5	129,150	(110,252)	18,903
Balances (in shares) at Jun. 30, 2019																													15,785,735
Balances at Jun. 30, 2019																													$ 2	120,835	(104,992)	15,845
Issuance of common stock upon exercise of common stock warrants																														431		431
Stock-based compensation																														146		146
Net loss																															(5,260)	(5,260)
Issuance of common stock and common stock warrants, net of offering costs (in shares)					26,124,828
Issuance of common stock and common stock warrants, net of offering costs					$ 3	$ 7,241		$ 7,244
Issuance of common stock warrants to placement agents’ designees		$ 497		$ 497
Issuance of common stock upon exercise of pre-funded warrants (in shares)																													4,313,031
Balances (in shares) at Sep. 30, 2019																													46,223,594
Balances at Sep. 30, 2019																													$ 5	129,150	(110,252)	18,903
Balances (in shares) at Dec. 31, 2019																													48,254,994
Balances at Dec. 31, 2019																													$ 5	129,608	(116,661)	12,952
Issuance of common stock, net of offering costs (in shares)																													12,503,806
Issuance of common stock, net of offering costs																													$ 1	97,033		97,034
Issuance of common stock upon exercise of common stock warrants (in shares)																													44,404,966
Issuance of common stock upon exercise of common stock warrants																													$ 5	25,946		$ 25,951
Issuance of common stock upon exercise of stock options (in shares)																													305,179			305,179
Issuance of common stock upon exercise of stock options																														402		$ 402
Stock-based compensation																														3,871		3,871
Net loss																															(18,359)	(18,359)
Issuance of common stock and common stock warrants, net of offering costs (in shares)																													4,000,000
Issuance of common stock and common stock warrants, net of offering costs																														8,722		8,722
Issuance of common stock warrants to placement agents’ designees																		$ 453		$ 453
Disgorgement of short-swing profits, net of costs																														652		652
Balances (in shares) at Sep. 30, 2020																													109,468,945
Balances at Sep. 30, 2020																													$ 11	266,687	(135,020)	131,678
Balances (in shares) at Jun. 30, 2020																													96,140,661
Balances at Jun. 30, 2020																													$ 10	167,160	(126,935)	40,235
Issuance of common stock, net of offering costs (in shares)																													12,503,806
Issuance of common stock, net of offering costs																													$ 1	97,033		97,034
Issuance of common stock upon exercise of common stock warrants (in shares)																													697,680
Issuance of common stock upon exercise of common stock warrants																														1,293		1,293
Issuance of common stock upon exercise of stock options (in shares)																													126,798
Issuance of common stock upon exercise of stock options																														286		286
Stock-based compensation																														915		915
Net loss																															(8,085)	(8,085)
Balances (in shares) at Sep. 30, 2020																													109,468,945
Balances at Sep. 30, 2020																													$ 11	$ 266,687	$ (135,020)	$ 131,678

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
The September 2019 Offering [Member]
Offering costs from issuance of common stock and warrants		$ 1,457		$ 1,457
The April 2019 Offering [Member]
Offering costs from issuance of common stock and warrants				1,579
Offering costs	$ 2,966		$ 2,966	$ 560
Offering costs from issuance of common stock and warrants			$ 1,278

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (18,359,000)	$ (12,236,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,846,000	2,854,000
Stock-based compensation	3,871,000	490,000
Non-cash interest expense		93,000
Non-cash interest expense related to sale of future royalties	1,401,000	1,560,000
Non-cash revenue related to sale of future royalties	(3,027,000)	(3,147,000)
Change in operating assets and liabilities:
Accounts receivable	3,369,000	1,237,000
Prepaid expenses and other assets	(1,384,000)	164,000
Accounts payable	810,000	136,000
Other accrued liabilities	(1,511,000)	(449,000)
Net cash used in operating activities	(12,984,000)	(9,298,000)
Cash flows from investing activities:
Purchase of property and equipment	(321,000)	(838,000)
Proceeds from sale of equipment	3,000
Net cash used in investing activities	(318,000)	(838,000)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of pre-funded warrants		1,083,000
Proceeds from issuance of common stock upon exercise of common stock warrants	25,951,000
Proceeds from issuance of common stock upon exercise of stock options	402,000
Disgorgement of short-swing profits, net of costs	652,000
Repayment of principal on secured promissory note payable to Oxford Finance		(1,250,000)
Net cash provided by financing activities	133,214,000	18,188,000
Net increase in cash and cash equivalents	119,912,000	8,052,000
Cash, cash equivalents and restricted cash at beginning of the period	13,526,000	11,506,000
Cash, cash equivalents and restricted cash at end of the period	133,438,000	19,558,000
Supplemental disclosure of cash flow information:
Interest paid		195,000
Supplemental disclosure of non-cash financing activity:
Issuance of warrants to placement agent’s representatives	453,000	100,000
Issuance of warrants to underwriters’ designees		830,000
Operating lease liabilities arising from obtaining right-of-use assets	1,022,000	1,929,000
Acquisition of property and equipment included in accounts payable	213,000	3,000
The March 2020 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of securities	9,175,000	2,540,000
ATM Program [Member]
Cash flows from financing activities:
Net proceeds from issuance of securities	97,034,000
The April 2019 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of securities in underwritten offering		8,074,000
The September 2019 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of securities in underwritten offering		$ 7,741,000

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. General Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, July 2007, On February 13, 2018, 0.22148 On March 2, 2020, “March 2020 4,000,000 2,000,000 one $2.50, five $10.0 $9.2 $775,000. 280,000 March 2020 one $3.125 five March 2020 $453,000 10 On June 8, 2020, $0.10 $0.0001 100,000,000 150,000,000. On July 13, 2020, 12,503,806 $100 July 8, 2020. $97 The Company's principal operations are based in South San Francisco, California, and it operates in one

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation December 31, 2019, 10 March 19, 2020 ( no 2 not Basis of Consolidation Use of Estimates Concentration of Credit Risk not The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one no Recent Accounting Pronouncements In August 2020, 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 815 40 none January 1, 2021. The Company has reviewed all other significant newly-issued accounting pronouncements that are not not not

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3 . Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three The three Level 1 Level 2 not Level 3 no The Company's money market funds are classified within Level 1 no September 30, 2020 $100,002,000 $15,000 September 30, 2020 December 31, 2019 no nine September 30, 2020 2019

Note 4 - Balance Sheet Componen

Note 4 - Balance Sheet Components	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	NOTE 4 . Balance Sheet Components (a) Cash and Cash Equivalents Cash and cash equivalents comprises the following: September 30, 2020 December 31, 2019 (in thousands) Cash at banks $ 33,436 $ 13,511 Money market funds 100,002 15 Total cash and cash equivalents $ 133,438 $ 13,526 (b) Accounts Receivable Accounts receivable comprises the following: September 30, 2020 December 31, 2019 (in thousands) Royalties receivable $ 250 $ 3,438 Customer service contracts - billed — 181 Accounts receivable $ 250 $ 3,619 The Company has provided no September 30, 2020 December 31, 2019. (c) Property and Equipment, Net Property and equipment, net consists of the following: September 30, 2020 December 31, 2019 (in thousands) Laboratory equipment $ 1,036 $ 537 Office and computer equipment 163 132 Total property and equipment 1,199 669 Less: accumulated depreciation (537 ) (459 ) Property and equipment, net $ 662 $ 210 Depreciation expense was $34,000 $131,000 three September 30, 2020 2019 $78,000 $386,000 nine September 30, 2020 2019 no nine September 30, 2020 2019 (d) Right-of-Use Assets , Net Right-of-use assets, net consists of the following: September 30, 2020 December 31, 2019 (in thousands) Facilities $ 2,588 $ 1,985 Office equipment 3 5 Right-of-use assets, net $ 2,591 $ 1,990 (e) Intangible Assets, Net Intangible assets comprise developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives ranging from 1.3 11.75 20 As of September 30, 2020 9.1 7.25 September 30, 2020 December 31, 2019 (in thousands) Purchased technology $ 22,100 $ 22,100 Intellectual property 80 80 Total cost 22,180 22,180 Less: accumulated amortization (6,386 ) (5,087 ) Intangible assets, net $ 15,794 $ 17,093 Total amortization expense for the three September 30, 2020 2019 $433,000 $433,000, nine September 30, 2020 2019 $1,299,000 $1,887,000, As of September 30, 2020 Year Ending December 31, Amount 2020 (three months remaining) $ 433 2021 1,732 2022 1,731 2023 1,732 2024 1,732 Thereafter 8,434 Total $ 15,794 (f) Other Accrued Liabilities Other accrued liabilities consist of the following: September 30, 2020 December 31, 2019 (in thousands) Accrued compensation $ 1,132 $ 903 Accrued clinical and manufacturing expenses 1,386 3,228 Accrued professional and consulting services 677 2 Reserve for return of royalties — 178 Other liabilities, current portion 529 254 Total $ 3,724 $ 4,565

Note 5 - Revenue

Note 5 - Revenue	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Revenue [Text Block]	NOTE 5 . Revenue Service Contracts with Customers Contract Balances. September 30, 2020 December 31, 2019 nil $181,000, September 30, 2020 December 31, 2019 $214,000 $21,000, Remaining Performance Obligations. September 30, 2020 December 31, 2019, no $18,000 $211,000, not 100% three not not Royalty Agreements Aviragen entered into a royalty-generating research and license agreement with GlaxoSmithKline, plc (“GSK”) in 1990 July 2019 April 30, 2020, three September 30, 2020 2019 nil $8,000, nine September 30, 2020 2019 $193,000 $772,000, 7% The Company also generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in 2009. September 2010, 4% December 2029, nine September 30, 2020 2019 $2,769,000 $2,964,000, 4% 6 $263,000 $352,000 three September 30, 2020 2019 $535,000 $2,116,000 nine September 30, 2020 2019 5% $13,000 $17,000 three September 30, 2020 2019 $165,000 $254,000 nine September 30, 2020 2019 The Company's royalty revenue is seasonal, in line with the flu season, so the majority of the Company's royalty revenue is earned in the first fourth

Note 6 - Liabilities Related to

Note 6 - Liabilities Related to Sale of Future Royalties	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Liabilities Related to Sale of Future Royalties [Text Block]	NOTE 6 . Liabilities Related to Sale of Future Royalties In April 2016, $20.0 first $3.0 15% $1.0 April 1, Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction is accounted for as a liability that is being amortized using the interest method over the life of the arrangement. The Company has no not not The following table shows the activity within the liability account during the nine September 30, 2020 Total liability related to sale of future royalties, start of period $ 16,332 Non-cash royalty revenue paid to HCRP (3,027 ) Non-cash interest expense recognized 1,401 Total liability related to sale of future royalties, end of period 14,706 Current portion (3,008 ) Long-term portion $ 11,698

Note 7 - Leases

Note 7 - Leases	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 7 . Leas es The Company has obtained the right of use for office and manufacturing facilities under five one one three one The Company obtained the right of use of real estate located in South San Francisco, California, in June 2015 April 30, 2020, five July 2019, April 30, 2025. December 31, 2019 ( 14 February 2018, February 28, 2021, no November 30, 2018. two July 31, 2021, no September 2021. September 2021. As of September 30, 2020 one 10.34% 2.58 The following table summarizes the Company's undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than twelve September 30, 2020 Year Ending December 31, 2020 (excluding the nine months ended September 30, 2020) $ 265 2021 1,719 2022 336 2023 348 2024 360 Thereafter 122 Undiscounted total 3,150 Less: imputed interest (419 ) Present value of future minimum payments 2,731 Current portion of operating lease liability (1,699 ) Operating lease liability, net of current portion $ 1,032 The Company presently has no no one Certain operating lease agreements for facilities include non-lease costs, such as common area maintenance, which are recorded as variable lease costs. Operating lease expenses for the three nine September 30, 2020 2019 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Lease cost (in thousands) (in thousands) Operating lease cost $ 235 $ 258 $ 636 $ 703 Short-term lease cost 4 4 10 11 Variable lease cost 29 44 53 132 Sublease income (54 ) (53 ) (163 ) (162 ) Total lease cost $ 214 $ 253 $ 536 $ 684 Net cash outflows associated with operating leases totaled $243,000 $253,000 three September 30, 2020 2019 $717,000 $740,000 nine September 30, 2020 2019

Note 8 - Secured Promissory Not

Note 8 - Secured Promissory Note Payable to Oxford Finance	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Secured Promissory Note Payable [Text Block]	NOTE 8 . Secured Promissory Note Payable to Oxford Finance On December 22, 2016, $5.0 $5.0 30 6.17%, four first 12 36 $325,000 The annual effective interest rate of the note, including the accretion of the final payment and the amortization of the debt discount, was approximately 10.5%. $82,000 $284,000 three nine September 30, 2019, $55,000 $191,000, November 4, 2019.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9 . Commitments and Contingencies (a) Leases The Company's lease commitments are detailed in Note 7. (b) Indemnifications In the ordinary course of business, the Company enters into agreements that may may third not may (c) From time to time the Company may not On August 4, 2020, September 4, 2020, March 24, 2020 June 15, 2020 two June 8, 2020. no October 14, 2020, On September 8, 2020, October 20, 2020, June 8, 2020 June 15, 2020 two June 9, 2020. no no October 9, 2020, November 9, 2020, November 9, 2020, On September 17, 2020, §14 1934 April 24, 2020, June 8 June 15, 2020, June 8, 2020, no no no Two substantially similar securities class actions were filed in the U.S. District Court for the Northern District of California, the first, titled Himmelberg v. Vaxart, Inc. et al. was filed on August 24, 2020 ( second September 1, 2020 ( September 17, 2020, one two 10b 5, 20 On October 23, 2020, 16 no The Company's legal costs incurred in its defense against these claims are expensed as incurred.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 1 0 . Stock holders' Equity (a) P referred Stock The Company is authorized to issue 5,000,000 $0.0001 may, 5,000,000 one may No no (b) Common Stock At the Company's annual meeting of stockholders held on June 8, 2020, 100,000,000 150,000,000 $0.10 $0.0001. June 8, 2020, Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company's directors and all other matters requiring stockholder action. Holders of common stock are entitled to one may no September 30, 2020 no In the event of the Company's voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company's assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no The Company had shares of common stock reserved for issuance as follows: September 30, 2020 December 31, 2019 Options issued and outstanding 6,320,530 1,811,652 PRSUs issued and outstanding 411,000 — Available for future grants of equity awards 1,554,328 295,180 Common stock warrants 1,244,974 43,370,162 Total 9,530,832 45,476,994 (c) Warrants The following warrants were outstanding as of September 30, 2020 none Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 5,000 $ 0.30 September 2024 Common Stock 224,797 $ 0.375 September 2024 Common Stock 225,966 $ 1.10 April 2024 Common Stock 111,931 $ 1.375 April 2024 Common Stock 316,584 $ 2.50 March 2025 Common Stock 269,496 $ 3.125 February 2025 Common Stock 80,286 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 1,244,974 The 280,000 March 2020 1 one $3.125 five February 27, 2020, March 2020 $453,000, $2.34 98%, 0.88%, zero 4.99 In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company's control, the holders of the unexercised common stock warrants exercisable for $0.30, $0.375, $1.10 $2.50 $3.125 February 2025 not

Note 11 - Equity Incentive Plan

Note 11 - Equity Incentive Plans	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 1 1 . Equity Incentive Plan s On April 23, 2019, 2019 “2019 may 2019 may 2019 not 2019 The aggregate number of shares of common stock authorized for issuance under the 2019 1,600,000 2019 June 8, 2020, 8,000,000 2019 2019 ten may In March 2020, 411,000 December 31, 2020, September 30, 2020 411,000 September 30, 2020 $101,000 $632,000 three nine September 30, 2020 On March 24, 2020, 2,610,000 $1.70 March 24, 2020) ( “March 25% twenty-four 24 May 1, 2020 April 1, 2022; not June 8, 2020, March A summary of stock option transactions in the nine September 30, 2020 Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2020 295,180 1,811,652 $ 2.74 2019 Plan Amendment 6,400,000 — $ — PRSUs granted, net of tax forfeitures (278,535 ) — $ — Granted (4,957,800 ) 4,957,800 $ 2.10 Exercised — (305,179 ) $ 1.32 Forfeited 85,910 (85,992 ) $ 0.39 Canceled 9,573 (57,751 ) $ 10.57 Balance at September 30, 2020 1,554,328 6,320,530 $ 2.27 As of September 30, 2020 6,320,530 $2.27, 9.18 $28.7 2,539,452 $2.79, 8.90 $10.8 $402,000 305,179 nine September 30, 2020 $1.6 No nine September 30, 2019 On June 15, 2020, 900,000 845,280 $2.46 25% first 75% three first 50% 2019 Vesting of the performance-based options would occur if the Company achieved a specified closing price during any ten November 30, 2020, one third $5.00, one third $7.50 one third $10.00, $2.46, 105%, 0.35%, zero 5.23 $0.31 $279,000, November 30, 2020, The tranches based on closing prices of $5.00, $7.50 $10.00 July 9, 2020, July 20, 2020 July 24, 2020, June 30, 2020, three September 30, 2020. nine September 30, 2020 2019 $1.98 $0.55, Nine Months Ended September 30, 2020 2019 Risk-free interest rate 0.40% 0.88% 1.89% 2.31% Expected term 5.22 - 10.00 Years 5.39 - 6.08 Years Expected volatility 94% 108% 83% 85% Dividend yield — % — % The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options and PRSUs was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (in thousands) (in thousands) Research and development $ 268 $ 63 $ 1,405 $ 222 General and administrative 647 83 2,466 268 Total stock-based compensation $ 915 $ 146 $ 3,871 $ 490 As of September 30, 2020 $5.4 2.35

Note 12 - Related Party Transac

Note 12 - Related Party Transaction	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 12. In April 2020 $652,000 16 1934,

Note 13 - Net Loss Per Share

Note 13 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 1 3 . Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Net loss $ (8,085 ) $ (5,260 ) $ (18,359 ) $ (12,236 ) Shares used to compute net loss per share – basic and diluted 107,718,578 16,249,032 81,121,045 12,748,665 Net loss per share – basic and diluted $ (0.08 ) $ (0.32 ) $ (0.23 ) $ (0.96 ) No three nine September 30, 2020 2019 The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because they would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Options to purchase common stock 6,335,797 1,965,910 3,596,816 1,466,495 PRSUs 411,000 — 286,500 — Warrants to purchase common stock 1,383,026 13,064,514 19,275,277 8,340,589 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 8,129,823 15,030,424 23,158,593 9,807,084

Note 14 - Restructuring Costs

Note 14 - Restructuring Costs	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	NOTE 1 4 . Restructuring Costs Restructuring liabilities primarily consist of the estimated future obligations for contract suspension costs. These restructuring liabilities, all of which are expected to be paid in the year ending December 31, 2020, The Company approved a reduction-in-force during the year ended December 31, 2019, three March 31, 2020. $2,252,000 three September 30, 2020, no nine September 30, 2020, not Cumulative restructuring costs incurred and a reconciliation of the change in related liabilities during the nine September 30, 2020 Suspension Severance Impairment of Contract Benefits Charges Other Total (in thousands) Cumulative cost incurred as of September 30, 2020 $ 2,252 $ 368 $ 1,272 $ 179 $ 4,071 Reconciliation of liabilities: Balance at December 31, 2019 $ 3,223 $ 368 $ — $ 57 $ 3,648 Period charges (971 ) — — 122 (849 ) Payments and settlements (2,252 ) (368 ) — (165 ) (2,785 ) Balance at September 30, 2020 $ — $ — $ — $ 14 $ 14

Note 15 - Subsequent Events

Note 15 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 15 . Subsequent Events On October 13, 2020, SM may $250 $0.3 October 13, 2020, 4.5% November 12, 2020 no Changes in the status of litigation since September 30, 2020 9. Litigation

Note 4 - Balance Sheet Compon_2

Note 4 - Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	September 30, 2020 December 31, 2019 (in thousands) Cash at banks $ 33,436 $ 13,511 Money market funds 100,002 15 Total cash and cash equivalents $ 133,438 $ 13,526
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	September 30, 2020 December 31, 2019 (in thousands) Royalties receivable $ 250 $ 3,438 Customer service contracts - billed — 181 Accounts receivable $ 250 $ 3,619
Property, Plant and Equipment [Table Text Block]	September 30, 2020 December 31, 2019 (in thousands) Laboratory equipment $ 1,036 $ 537 Office and computer equipment 163 132 Total property and equipment 1,199 669 Less: accumulated depreciation (537 ) (459 ) Property and equipment, net $ 662 $ 210
Lessee, Operating Lease, Right-of-Use Assets [Table Text Block]	September 30, 2020 December 31, 2019 (in thousands) Facilities $ 2,588 $ 1,985 Office equipment 3 5 Right-of-use assets, net $ 2,591 $ 1,990
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 2020 December 31, 2019 (in thousands) Purchased technology $ 22,100 $ 22,100 Intellectual property 80 80 Total cost 22,180 22,180 Less: accumulated amortization (6,386 ) (5,087 ) Intangible assets, net $ 15,794 $ 17,093
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending December 31, Amount 2020 (three months remaining) $ 433 2021 1,732 2022 1,731 2023 1,732 2024 1,732 Thereafter 8,434 Total $ 15,794
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2020 December 31, 2019 (in thousands) Accrued compensation $ 1,132 $ 903 Accrued clinical and manufacturing expenses 1,386 3,228 Accrued professional and consulting services 677 2 Reserve for return of royalties — 178 Other liabilities, current portion 529 254 Total $ 3,724 $ 4,565

Note 6 - Liabilities Related _2

Note 6 - Liabilities Related to Sale of Future Royalties (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Total liability related to sale of future royalties, start of period $ 16,332 Non-cash royalty revenue paid to HCRP (3,027 ) Non-cash interest expense recognized 1,401 Total liability related to sale of future royalties, end of period 14,706 Current portion (3,008 ) Long-term portion $ 11,698

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2020 (excluding the nine months ended September 30, 2020) $ 265 2021 1,719 2022 336 2023 348 2024 360 Thereafter 122 Undiscounted total 3,150 Less: imputed interest (419 ) Present value of future minimum payments 2,731 Current portion of operating lease liability (1,699 ) Operating lease liability, net of current portion $ 1,032
Lease, Cost [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Lease cost (in thousands) (in thousands) Operating lease cost $ 235 $ 258 $ 636 $ 703 Short-term lease cost 4 4 10 11 Variable lease cost 29 44 53 132 Sublease income (54 ) (53 ) (163 ) (162 ) Total lease cost $ 214 $ 253 $ 536 $ 684

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Common Stock Reserved for Issuance [Table Text Block]	September 30, 2020 December 31, 2019 Options issued and outstanding 6,320,530 1,811,652 PRSUs issued and outstanding 411,000 — Available for future grants of equity awards 1,554,328 295,180 Common stock warrants 1,244,974 43,370,162 Total 9,530,832 45,476,994
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 5,000 $ 0.30 September 2024 Common Stock 224,797 $ 0.375 September 2024 Common Stock 225,966 $ 1.10 April 2024 Common Stock 111,931 $ 1.375 April 2024 Common Stock 316,584 $ 2.50 March 2025 Common Stock 269,496 $ 3.125 February 2025 Common Stock 80,286 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 1,244,974

Note 11 - Equity Incentive Pl_2

Note 11 - Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2020 295,180 1,811,652 $ 2.74 2019 Plan Amendment 6,400,000 — $ — PRSUs granted, net of tax forfeitures (278,535 ) — $ — Granted (4,957,800 ) 4,957,800 $ 2.10 Exercised — (305,179 ) $ 1.32 Forfeited 85,910 (85,992 ) $ 0.39 Canceled 9,573 (57,751 ) $ 10.57 Balance at September 30, 2020 1,554,328 6,320,530 $ 2.27
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2020 2019 Risk-free interest rate 0.40% 0.88% 1.89% 2.31% Expected term 5.22 - 10.00 Years 5.39 - 6.08 Years Expected volatility 94% 108% 83% 85% Dividend yield — % — %
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (in thousands) (in thousands) Research and development $ 268 $ 63 $ 1,405 $ 222 General and administrative 647 83 2,466 268 Total stock-based compensation $ 915 $ 146 $ 3,871 $ 490

Note 13 - Net Loss Per Share (T

Note 13 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Net loss $ (8,085 ) $ (5,260 ) $ (18,359 ) $ (12,236 ) Shares used to compute net loss per share – basic and diluted 107,718,578 16,249,032 81,121,045 12,748,665 Net loss per share – basic and diluted $ (0.08 ) $ (0.32 ) $ (0.23 ) $ (0.96 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Options to purchase common stock 6,335,797 1,965,910 3,596,816 1,466,495 PRSUs 411,000 — 286,500 — Warrants to purchase common stock 1,383,026 13,064,514 19,275,277 8,340,589 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 8,129,823 15,030,424 23,158,593 9,807,084

Note 14 - Restructuring Costs (

Note 14 - Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Suspension Severance Impairment of Contract Benefits Charges Other Total (in thousands) Cumulative cost incurred as of September 30, 2020 $ 2,252 $ 368 $ 1,272 $ 179 $ 4,071 Reconciliation of liabilities: Balance at December 31, 2019 $ 3,223 $ 368 $ — $ 57 $ 3,648 Period charges (971 ) — — 122 (849 ) Payments and settlements (2,252 ) (368 ) — (165 ) (2,785 ) Balance at September 30, 2020 $ — $ — $ — $ 14 $ 14

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	Jul. 13, 2020	Mar. 02, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Jun. 08, 2020	Jun. 07, 2020	Dec. 31, 2019	Feb. 13, 2018
Conversion of Stock, Shares Issued (in shares)									0.22148
Proceeds from Issuance or Sale of Equity, Total		$ 10,000,000
Proceeds from Issuance or Sale of Equity, Net		9,200,000
Payments of Stock Issuance Costs		$ 775,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001	$ 0.0001		$ 0.0001	$ 0.10	$ 0.0001
Common Stock, Shares Authorized (in shares)			150,000,000	150,000,000		150,000,000	100,000,000	150,000,000
Stock Issued During Period, Value, New Issues			$ 97,034,000	$ 97,034,000	$ 2,440,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001	$ 0.0001		$ 0.0001	$ 0.10	$ 0.0001
The March 2020 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.50
Warrants and Rights Outstanding, Term (Year)		5 years
Warrants and Rights Outstanding		$ 453,000
The March 2020 Offering Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		280,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 3.125
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Issued During Period (in shares)		280,000
Warrants and Rights Outstanding		$ 453,000
The March 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		4,000,000
Proceeds from Issuance of Common Stock				$ 9,175,000	2,540,000
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)	12,503,806
Stock Issued During Period, Value, New Issues	$ 100,000,000
Proceeds from Issuance of Common Stock	$ 97,000,000			$ 97,034,000

Note 3 - Fair Value of Financ_2

Note 3 - Fair Value of Financial Instruments (Details Textual) - Fair Value, Recurring [Member] - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Financial Liabilities Fair Value Disclosure, Total	$ 0		$ 0
Money Market Funds [Member]
Cash and Cash Equivalents, Fair Value Disclosure	$ 100,002,000	$ 15,000

Note 4 - Balance Sheet Compon_3

Note 4 - Balance Sheet Components (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accounts Receivable, Allowance for Credit Loss, Current	$ 0		$ 0		$ 0
Depreciation, Total	34,000	$ 131,000	78,000	$ 386,000
Impairment of Property and Equipment			0	0
Amortization of Intangible Assets, Total	$ 433,000	$ 433,000	$ 1,299,000	$ 1,887,000
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			20 years
Finite-Lived Intangible Asset, Remaining Life (Year)			7 years 91 days
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)			9 years 36 days
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			1 year 109 days
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			11 years 273 days

Note 4 - Balance Sheet Compon_4

Note 4 - Balance Sheet Components - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Cash at banks	$ 33,436	$ 13,511
Money market funds	100,002	15
Total cash and cash equivalents	$ 133,438	$ 13,526	$ 19,558	$ 11,506

Note 4 - Balance Sheet Compon_5

Note 4 - Balance Sheet Components - Accounts Receivable, Net of Allowance (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable	$ 250	$ 3,619
Royalty [Member]
Accounts receivable	250	3,438
Customer Service Contracts [Member]
Accounts receivable		$ 181

Note 4 - Balance Sheet Compon_6

Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property and equipment, gross	$ 1,199	$ 669
Less: accumulated depreciation	(537)	(459)
Property and equipment, net	662	210
Laboratory Equipment [Member]
Property and equipment, gross	1,036	537
Office Equipment [Member]
Property and equipment, gross	$ 163	$ 132

Note 4 - Balance Sheet Compon_7

Note 4 - Balance Sheet Components - Right-of-Use Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Right-of-use assets, net	$ 2,591	$ 1,990
Facilities [Member]
Right-of-use assets, net	2,588	1,985
Office Equipment [Member]
Right-of-use assets, net	$ 3	$ 5

Note 4 - Balance Sheet Compon_8

Note 4 - Balance Sheet Components - Intangible assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Intangible assets, gross	$ 22,180	$ 22,180
Less: accumulated amortization	(6,386)	(5,087)
Intangible assets, net	15,794	17,093
Purchased Technology [Member]
Intangible assets, gross	22,100	22,100
Intellectual Property [Member]
Intangible assets, gross	$ 80	$ 80

Note 4 - Balance Sheet Compon_9

Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2020USD ($)
2020 (three months remaining)	$ 433
2021	1,732
2022	1,731
2023	1,732
2024	1,732
Thereafter	8,434
Total	$ 15,794

Note 4 - Balance Sheet Compo_10

Note 4 - Balance Sheet Components - Accrued liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accrued compensation	$ 1,132	$ 903
Accrued clinical and manufacturing expenses	1,386	3,228
Accrued professional and consulting services	677	2
Reserve for return of royalties		178
Other liabilities, current portion	529	254
Total	$ 3,724	$ 4,565

Note 5 - Revenue 1 (Details Tex

Note 5 - Revenue 1 (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total	$ 0		$ 0		$ 181,000
Contract With Customer, Asset, Revenue Recognized	214,000		214,000		21,000
Contract with Customer, Liability, Total	0		0		0
Revenue, Remaining Performance Obligation, Amount	18,000		18,000		$ 211,000
Revenue from Contract with Customer, Including Assessed Tax	265,000	$ 454,000	3,690,000	$ 5,946,000
Income Tax Expense (Benefit), Total	26,000	31,000	$ 205,000	294,000
Foreign Tax Authority [Member] | National Tax Agency, Japan [Member]
Royalty Withholding Tax			5.00%
Income Tax Expense (Benefit), Total	13,000	17,000	$ 165,000	254,000
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax		8,000	2,962,000	3,736,000
Royalty [Member] | GSK Research and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax		8,000	$ 193,000	772,000
Royalty Percentage			7.00%
Royalty [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax			$ 2,769,000	2,964,000
Royalty Percentage			4.00%		4.00%
Non-cash Royalty Revenue, Related to Sale of Future Royalties	$ 263,000	$ 352,000	$ 535,000	$ 2,116,000

Note 5 - Revenue 2 (Details Tex

Note 5 - Revenue 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01	Sep. 30, 2020
Revenue, Remaining Performance Obligation, Percentage	100.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	90 days

Note 6 - Liabilities Related _3

Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual) - HCRP [Member] $ in Millions	1 Months Ended
	Apr. 30, 2016USD ($)
Proceeds from Sale of Future Royalties, Net	$ 20
Royalty Interest Due Each Year	$ 3
Royalty Interest, Percentage of Additional Royalties Due Each Year	15.00%
Royalty Interest, Additional Royalties Due Each Year	$ 1

Note 6 - Liabilities Related _4

Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Current portion	$ (3,008)	$ (2,916)
Long-term portion	11,698	$ 13,416
HealthCare Royalty Partners III, L.P. [Member] | Royalty Arrangement [Member]
Total liability related to sale of future royalties, start of period	16,332
Non-cash royalty revenue paid to HCRP	(3,027)
Non-cash interest expense recognized	1,401
Total liability related to sale of future royalties, end of period	14,706
Current portion	(3,008)
Long-term portion	$ 11,698

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Lessee, Operating Lease, Number of Right-of-Use Leases	5		5
Lessee, Operating Lease, Number of Right-of-Use Leases, Terminated	1		1
Lessee, Operating Lease, Number of Right-of-Use Leases, Subleased	1		1
Lessee, Operating Lease, Number Leases Exceeding One Year	3		3
Lessee, Operating Lease, Renewal Term (Year)	5 years		5 years
Operating Lease, Weighted Average Discount Rate, Percent	10.34%		10.34%
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 211 days		2 years 211 days
Lessee, Finance Lease, Number of Leases	0		0
Short-term Lease Commitment, Amount	$ 0		$ 0
Operating Lease, Payments	$ 243,000	$ 253,000	$ 717,000	$ 740,000

Note 7 - Leases - Lease Liabili

Note 7 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
2020 (excluding the nine months ended September 30, 2020)	$ 265
2021	1,719
2022	336
2023	348
2024	360
Thereafter	122
Undiscounted total	3,150
Less: imputed interest	(419)
Present value of future minimum payments	2,731
Current portion of operating lease liability	(1,699)	$ (841)
Operating lease liability, net of current portion	$ 1,032	$ 1,472

Note 7 - Leases - Operating Lea

Note 7 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating lease cost	$ 235	$ 258	$ 636	$ 703
Short-term lease cost	4	4	10	11
Variable lease cost	29	44	53	132
Sublease income	(54)	(53)	(163)	(162)
Total lease cost	$ 214	$ 253	$ 536	$ 684

Note 8 - Secured Promissory N_2

Note 8 - Secured Promissory Note Payable to Oxford Finance (Details Textual) - Loan Agreement [Member] - Oxford Finance [Member] - USD ($)	Dec. 22, 2016	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Long-term Debt, Gross	$ 5,000,000
Debt Instrument, Term (Year)	4 years
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	$ 325,000
Debt Instrument, Interest Rate, Effective Percentage	10.50%
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total		$ 82,000	$ 55,000	$ 284,000	$ 191,000
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.17%

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual)	6 Months Ended
	Jun. 30, 2020USD ($)	Sep. 30, 2020$ / sharesshares	Jun. 08, 2020$ / sharesshares	Jun. 07, 2020$ / sharesshares	Mar. 02, 2020USD ($)yr$ / sharesshares	Dec. 31, 2019$ / sharesshares
Preferred Stock, Shares Authorized (in shares) | shares		5,000,000				5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.10		$ 0.0001
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		0				0
Common Stock, Shares Authorized (in shares) | shares		150,000,000	150,000,000	100,000,000		150,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.10		$ 0.0001
Dividends, Total | $	$ 0
The March 2020 Offering Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					280,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 3.125
Warrants and Rights Outstanding, Term (Year)					5 years
Warrants and Rights Outstanding | $					$ 453,000
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input					2.34
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input					0.98
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0.0088
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0
The March 2020 Offering Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr					4.99
First Set of Warrants Expiring September 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		0.30
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		0.30
Second Set of Warrants Expiring April 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		1.375
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		0.375
First Set of Warrants Expiring April 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		1.10
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		1.10
Warrants Expiring March 2025 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		2.50
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		2.50
Warrants Expiring March 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		3.125
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		$ 3.125

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Sep. 30, 2020	Dec. 31, 2019
Common stock reserved for issuance (in shares)	9,530,832	45,476,994
Options Issued and Outstanding [Member]
Common stock reserved for issuance (in shares)	6,320,530	1,811,652
Performance-based Restricted Stock Units (PRSUs) [Member]
Common stock reserved for issuance (in shares)	411,000
Options Available for Future Grants [Member]
Common stock reserved for issuance (in shares)	1,554,328	295,180
Common Warrants [Member]
Common stock reserved for issuance (in shares)	1,244,974	43,370,162

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Sep. 30, 2020$ / sharesshares
Warrants outstanding (in shares)	1,244,974
First Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	5,000
Exercise Price (in dollars per share) | $ / shares	$ 0.30
Second Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	224,797
Exercise Price (in dollars per share) | $ / shares	$ 0.375
First Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	225,966
Exercise Price (in dollars per share) | $ / shares	$ 1.10
Second Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	111,931
Exercise Price (in dollars per share) | $ / shares	$ 1.375
Warrants Expiring March 2025 [Member]
Warrants outstanding (in shares)	316,584
Exercise Price (in dollars per share) | $ / shares	$ 2.50
Warrants Expiring February 2025 [Member]
Warrants outstanding (in shares)	269,496
Exercise Price (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring March 2024 [Member]
Warrants outstanding (in shares)	80,286
Exercise Price (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring December 2026 [Member]
Warrants outstanding (in shares)	10,914
Exercise Price (in dollars per share) | $ / shares	$ 22.99

Note 11 - Equity Incentive Pl_3

Note 11 - Equity Incentive Plans (Details Textual) - USD ($)	Jul. 24, 2020	Jul. 20, 2020	Jul. 09, 2020	Jun. 23, 2020	Jun. 15, 2020	Mar. 24, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Apr. 23, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						2,610,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)						$ 1.70				$ 2.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)								6,320,530		6,320,530		1,811,652
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)								$ 2.27		$ 2.27		$ 2.74
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)										9 years 65 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value								$ 28,700,000		$ 28,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)								2,539,452		2,539,452
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)								$ 2.79		$ 2.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)										8 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value								$ 10,800,000		$ 10,800,000
Proceeds from Stock Options Exercised										$ 402,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)										305,179	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value										$ 1,600,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								$ 5,400,000		$ 5,400,000
Performance-based Restricted Stock Units (PRSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)							411,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)								411,000		411,000
Share-based Payment Arrangement, Expense								$ 101,000		$ 632,000
March Option Awards [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						24 years
Performance-based Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					900,000
Share Price (in dollars per share)					$ 2.46
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					105.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					0.35%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)					5 years 83 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value					$ 279,000
Performance-based Options [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)			$ 5		$ 5
Performance-based Options [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)		$ 7.50			$ 7.50
Performance-based Options [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)	$ 10				$ 10
Time-based Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					845,280
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 2.46
Time-based Options [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%
Time-based Options [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					75.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					3 years
Time-based Options [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Accelerated Vesting Percentage					50.00%
Performance-based Options and Time-based Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 2.46
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense								$ 915,000	$ 146,000	$ 3,871,000	$ 490,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)										$ 1.98	$ 0.55
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										2 years 127 days
The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				8,000,000									1,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years

Note 11 - Equity Incentive Pl_4

Note 11 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) - $ / shares	Mar. 24, 2020	Sep. 30, 2020	Sep. 30, 2019
Shares available for grant, balance (in shares)		295,180
Number of options outstanding, beginning balance (in shares)		1,811,652
Weighted average exercise price, balance (in dollars per share)		$ 2.74
Shares availabe for grant, 2019 Plan Amendment (in shares)		6,400,000
Shares available for grant, granted (in shares)		(4,957,800)
Number of options outstanding, granted (in shares)		4,957,800
Weighted average exercise price, granted (in dollars per share)	$ 1.70	$ 2.10
Number of options outstanding, exercised (in shares)		(305,179)	0
Weighted average exercise price, exercised (in dollars per share)		$ 1.32
Shares available for grant, forfeited (in shares)		85,910
Number of options outstanding, forfeited (in shares)		(85,992)
Weighted average exercise price, forfeited (in dollars per share)		$ 0.39
Shares available for grant, canceled (in shares)		9,573
Number of options outstanding, canceled (in shares)		(57,751)
Weighted average exercise price, canceled (in dollars per share)		$ 10.57
Shares available for grant, balance (in shares)		1,554,328
Number of options outstanding, balance (in shares)		6,320,530
Weighted average exercise price, balance (in dollars per share)		$ 2.27
Performance-based Restricted Stock Units (PRSUs) [Member]
Shares available for grant, PRSU's granted (in shares)		(278,535)

Note 11 - Equity Incentive Pl_5

Note 11 - Equity Incentive Plans - Assumptions of Options (Details) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Dividend yield
Minimum [Member]
Risk-free interest rate	0.40%	1.89%
Expected term (Year)	5 years 80 days	5 years 142 days
Expected volatility	94.00%	83.00%
Maximum [Member]
Risk-free interest rate	0.88%	2.31%
Expected term (Year)	10 years	6 years 29 days
Expected volatility	108.00%	85.00%

Note 11 - Equity Incentive Pl_6

Note 11 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - Share-based Payment Arrangement, Option [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Expense	$ 915	$ 146	$ 3,871	$ 490
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	268	63	1,405	222
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense	$ 647	$ 83	$ 2,466	$ 268

Note 12 - Related Party Trans_2

Note 12 - Related Party Transaction (Details Textual)	1 Months Ended
	Apr. 30, 2020USD ($)
Disgorgement of Stockholder Short-swing Profits [Member]
Related Party Transaction, Amounts of Transaction	$ 652,000

Note 13 - Net Loss Per Share (D

Note 13 - Net Loss Per Share (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Dilutive Securities, Effect on Basic Earnings Per Share, Total	$ 0	$ 0	$ 0	$ 0

Note 13 - Net Loss Per Share At

Note 13 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net loss	$ (8,085)	$ (5,260)	$ (18,359)	$ (12,236)
Shares used to compute net loss per share - basic and diluted (in shares)	107,718,578	16,249,032	81,121,045	12,748,665
Net loss per share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.32)	$ (0.23)	$ (0.96)

Note 13 - Net Loss Per Share _2

Note 13 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	8,129,823	15,030,424	23,158,593	9,807,084
Share-based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	6,335,797	1,965,910	3,596,816	1,466,495
Performance-based Restricted Stock Units (PRSUs) [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	411,000		286,500
Warrant [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	1,383,026	13,064,514	19,275,277	8,340,589

Note 14 - Restructuring Costs_2

Note 14 - Restructuring Costs (Details Textual)	9 Months Ended
	Sep. 30, 2020USD ($)
Payments for Restructuring	$ 2,785,000
Contract Termination [Member]
Payments for Restructuring	$ 2,252,000

Note 14 - Restructuring Costs -

Note 14 - Restructuring Costs - Restructuring Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Cumulative cost incurred	$ 4,071,000		$ 4,071,000
Balance			3,648,000
Restructuring costs	(952,000)		(849,000)
Payments and settlements			(2,785,000)
Balance	14,000		14,000
Contract Termination [Member]
Cumulative cost incurred	2,252,000		2,252,000
Balance			3,223,000
Restructuring costs			(971,000)
Payments and settlements			(2,252,000)
Balance
Employee Severance [Member]
Cumulative cost incurred	368,000		368,000
Balance			368,000
Restructuring costs
Payments and settlements			(368,000)
Balance
Impairment Charges [Member]
Cumulative cost incurred	1,272,000		1,272,000
Balance
Restructuring costs
Payments and settlements
Balance
Other Restructuring [Member]
Cumulative cost incurred	179,000		179,000
Balance			57,000
Restructuring costs			122,000
Payments and settlements			(165,000)
Balance	$ 14,000		$ 14,000

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	Oct. 13, 2020	Mar. 02, 2020	Nov. 12, 2020
Payments of Stock Issuance Costs		$ 775,000
Subsequent Event [Member]
Stock Issued During Period, Value, Exercise of Common Stock Warrants (in shares)			9
Subsequent Event [Member] | Open Market Sale Agreement [Member]
Open Market Sale Agreement, Maximum Aggregate Offering Price	$ 250,000,000
Payments of Stock Issuance Costs	$ 300,000
Open Market Sale Agreement, Sales Commission, Percentage	4.50%